The title compound, （E）-4-（3-oxo-3-（（4-（N-（pyrimidin-2-yl）sulfamoyl）-phenyl）ami- no）prop- 1-en- 1-yl）- 1,2-phenylene diacetate dimethanol, was synthesized by the reaction of caffeic acid with sulfadiazine and characterized by FT-IR, 1H-NMR spectroscopy, ESI-MS and X-ray single-crystal diffraction. It crystallizes in triclinic, space group P1 with a = 10.302（7）, b = 11.621（8）, c = 12.107（8）A, a = 100.904（9）, β = 102.624（8）, y = 95.501（9）°, V= 1374.5（15）A3, Z= 2, F（000） = 588, D,= 1.354 Mg/m3, Mr = 560.57,μ= 0.176 mm-1, 2 = 0.71073 A, the final R = 0.0666 and wR = 0.1950 for 4774 observed reflections with I 〉 2σ（I）.
The title compound, （E）-N,N′-dicyclohexyl-1-（3-（3,4-dihydroxyphenyl）acryloyl）- urea （DDA）, has been synthesized and characterized by FT-IR and 1H-NMR spectroscopy, ESI- MS, and X-ray single-crystal diffraction. Its crystallizes in monoclinic, space group C2/c with a = 20.483（12）, b = 11.153（6）, c = 21.134（12） , β = 117.098（7）, V = 4298（4） 3, Z = 8, F（000） = 1664, Dc = 1.195 Mg/m3, Mr = 386.48, μ= 0.082 mm-1, the final R = 0.0474 and wR = 0.1370 for 4853 observed reflections with I 〉 2σ（I）.
